RESUMEN
There is little evidence to date to indicate if mesoaccumbens dopamine function at the neurochemical level is altered during early abstinence from chronic i.v. nicotine self-administration. Thus, a quantitative microdialysis (no-net-flux) approach was used to measure basal extracellular concentrations and extraction fractions of dopamine in the nucleus accumbens (ACB) of rats that self-administered nicotine i.v. for 25 days, as well as in rats serving as yoked comparison groups (yoked nicotine and yoked saline). After 24-48 h of the final self-administration session, there was a significant reduction in basal extracellular dopamine levels in the ACB of the self-administration group compared with the yoked saline group (1.35+/-0.15 nM versus 3.70+/-0.28 nM). The basal extracellular dopamine levels in the yoked nicotine group (1.46+/-0.20 nM) were not significantly different compared with the nicotine self-administration group. The in vivo extraction fraction of dopamine, an indirect measure of dopamine uptake, was significantly increased in the nicotine self-administration (86%) and yoked nicotine (91%) groups compared with the yoked saline group (77%). In addition, a marked reduction in the elevation of extracellular dopamine levels in the ACB occurred after a nicotine challenge as measured by conventional microdialysis in the self-administration (112% of basal) and yoked nicotine (121% of basal) groups as compared with a yoked saline (154% of basal) group. The reduced basal ACB dopamine levels in the nicotine groups during early abstinence appears to be due to increased clearance, suggesting increased dopamine uptake is occurring as a result of the chronic nicotine treatment. The reduced elevation of extracellular dopamine levels in the ACB upon nicotine challenge suggests a functional desensitization or downregulation phenomenon involving acetylcholine receptors (nicotinic nAChRs). Overall, these results provide clear evidence for a neuroadaptive change that alters dopamine transmission in the ACB during abstinence from chronic i.v. nicotine exposure.
Asunto(s)
Dopamina/fisiología , Nicotina/farmacología , Agonistas Nicotínicos/farmacología , Núcleo Accumbens/fisiología , Adaptación Fisiológica/efectos de los fármacos , Animales , Cromatografía Líquida de Alta Presión , Condicionamiento Operante/efectos de los fármacos , Dopamina/metabolismo , Espacio Extracelular/efectos de los fármacos , Espacio Extracelular/metabolismo , Infusiones Intravenosas , Masculino , Microdiálisis , Nicotina/administración & dosificación , Agonistas Nicotínicos/administración & dosificación , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Ratas , Ratas Long-Evans , Autoadministración , Síndrome de Abstinencia a Sustancias/metabolismo , Transmisión SinápticaRESUMEN
We examined the effects of nicotine perfusion into the ventral tegmental area (VTA) on extracellular dopamine (DA) levels in rats using in vivo microdialysis. Local perfusion with nicotine for 80 min (10-100 microM) modestly increased (approximately 105-131% of basal) the extracellular DA levels in the VTA of rats that had been pretreated with saline for 5 days. In animals that had been pretreated with nicotine for 5 days (0.3 mg/kg, s.c.), perfusion with nicotine for 80 min (10-100 microM) dose-dependently increased the extracellular DA levels in the VTA of rats and did so to a greater extent than in saline-pretreated animals (125-171% of basal). Co-perfusion through the dialysis probe with 100 microM mecamylamine, a nonselective nicotinic acetylcholine receptor (nAChR) antagonist, or 100 microM dihydro-beta-erythroidine, a high affinity and competitive nAChR antagonist, attenuated the enhancement of extracellular DA levels produced by 100 microM nicotine alone. These results suggest that local nicotine challenge potentiated the somatodendritic DA release after nicotine preexposure by stimulation of high-affinity nAChRs in the VTA.
Asunto(s)
Dendritas/fisiología , Dopamina/metabolismo , Nicotina/farmacología , Área Tegmental Ventral/fisiología , Animales , Dendritas/efectos de los fármacos , Cinética , Masculino , Mecamilamina/administración & dosificación , Mecamilamina/farmacología , Microdiálisis , Perfusión , Ratas , Ratas Long-Evans , Área Tegmental Ventral/efectos de los fármacosRESUMEN
The objectives of the present study were to examine the effects of acute and chronic nicotine on dopamine (DA) release in the ventral tegmental area (VTA) of Long-Evans rats using in vivo microdialysis. Systemic application of acute nicotine (0.1-0.3 mg/kg, s.c.) significantly increased (145% of baseline) DA release in the VTA. Chronic exposure to nicotine (0.3 mg/kg, s.c.) for 5 days followed by a challenge dose of nicotine (0.3 mg/kg, s.c.) also produced significant enhancement (136% of baseline) of DA release in the VTA. The results suggest that both acute and chronic nicotine treatment exert stimulatory effects on somatodendritic DA release in the VTA. The enhancement of DA release to subsequent challenge nicotine may be susceptible to mild desensitization.
Asunto(s)
Dendritas/efectos de los fármacos , Dopamina/metabolismo , Nicotina/farmacología , Tabaquismo/metabolismo , Área Tegmental Ventral/efectos de los fármacos , Animales , Dendritas/metabolismo , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Espacio Extracelular/efectos de los fármacos , Espacio Extracelular/metabolismo , Masculino , Microdiálisis , Ratas , Ratas Long-Evans , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/metabolismo , Tabaquismo/fisiopatología , Área Tegmental Ventral/citología , Área Tegmental Ventral/metabolismoRESUMEN
RATIONALE: The pedunculopontine tegmental nucleus (PPTg) is part of the neuronal circuit activated by self-administered nicotine. The cholinergic neurons of the PPTg comprise a prominent projection to midbrain dopamine neurons. However, anatomical studies of Fos expression suggest that nicotine targets primarily non-cholinergic neurons in the PPTg, especially GABAergic and glutamatergic neurons. OBJECTIVE: The objective of these experiments was to examine the role of GABA manipulations in the PPTg on nicotine self-administration. METHODS AND RESULTS: Rats trained to self-administer nicotine or cocaine intravenously were prepared with brain microcannulae directed to the PPTg. Intra-PPTg microinfusions of the GABA agonists muscimol (10-50 ng) and baclofen (30-60 ng) reduced nicotine self-administration maintained on a fixed-ratio schedule of reinforcement (30 microg/kg per infusion); self-administration of cocaine (0.3 mg/kg per infusion) under an identical schedule was not affected. Muscimol and baclofen were also examined after intra-PPTg microinfusion in animals trained to self-administer nicotine on a progressive-ratio schedule (10 and 30 microg/kg per infusion). Progressive-ratio responding was sensitive to pharmacological manipulations such as a change in the nicotine dose available for self-administration, or intra-PPTg microinfusion of the nicotinic antagonist dihydro-beta-erythroidine (30 microg). However, nicotine self-administration on a progressive-ratio schedule was not altered by intra-PPTg microinfusions of GABA agonists. CONCLUSIONS: These data confirm that the PPTg is involved in nicotine self-administration, a conclusion that is independent of the schedule of reinforcement that is used. GABAergic mechanisms in the PPTg play a selective role in nicotine reinforcement compared to cocaine, and that role is restricted to the characteristics of reinforcement measured by fixed-ratio responding.
Asunto(s)
Agonistas del GABA/farmacología , Nicotina/administración & dosificación , Agonistas Nicotínicos/administración & dosificación , Tegmento Mesencefálico/efectos de los fármacos , Animales , Tronco Encefálico/efectos de los fármacos , Tronco Encefálico/fisiología , Cocaína/administración & dosificación , Inhibidores de Captación de Dopamina/administración & dosificación , Relación Dosis-Respuesta a Droga , Masculino , Ratas , Ratas Long-Evans , Esquema de Refuerzo , Autoadministración , Tegmento Mesencefálico/fisiologíaRESUMEN
RATIONALE: Various compounds believed to selectively interact with the 5-HT(2C) receptor have been demonstrated to alter the functioning of ascending dopamine systems. We postulated that this functional interaction may extend to the behavioural effects of drugs of abuse whose rewarding properties are critically dependent upon mesolimbic DA activity. OBJECTIVES: The present studies focussed on interactions between 5-HT(2C) receptor function and behaviours either supported or induced by nicotine. METHODS: The effect of Ro 60-0175, a 5-HT(2C) agonist, was assessed for its ability to modify 1) nicotine-induced locomotor activity in nicotine-treated rats, 2) lever pressing maintained by either food or IV administration of nicotine, and 3) the development of nicotine-induced hyperactivity. The specificity of this effect was further measured in locomotor activity studies by additional administration of the selective 5-HT(2C) antagonist SB 242,084. RESULTS: Ro 60-0175 (0.3-3 mg/kg SC) dose-dependently reduced nicotine-induced activity, an effect which was reversed by SB 242,084 (0.5 mg/kg IP), thus confirming receptor selectivity of the response. Responding both for food and nicotine on an FR5TO1 min schedule of reinforcement was reduced by Ro 60-0175 (0.1-1 mg/kg) with proportionally similar effects on responses for both types of reinforcer. Co-administration of Ro 60-0175 (1 mg/kg SC) and nicotine (0.4 mg/kg SC) for 10 days blocked the sensitised response that developed in subjects treated with nicotine alone. CONCLUSIONS: The present data support an involvement for the 5-HT(2C) receptor in mediating mesolimbic DA functioning as assessed by changes in behaviours indicative of nicotine reward.
Asunto(s)
Condicionamiento Operante/efectos de los fármacos , Actividad Motora/efectos de los fármacos , Nicotina/farmacología , Agonistas Nicotínicos/farmacología , Receptores de Serotonina/efectos de los fármacos , Aminopiridinas/farmacología , Animales , Relación Dosis-Respuesta a Droga , Etilaminas/farmacología , Alimentos , Indoles/farmacología , Inyecciones Intravenosas , Masculino , Nicotina/administración & dosificación , Agonistas Nicotínicos/administración & dosificación , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2C , Refuerzo en Psicología , Antagonistas de la Serotonina/farmacología , Agonistas de Receptores de Serotonina/farmacologíaRESUMEN
AIMS: To determine the topography of cigarette smoking and the subjective and physiological effects of abstinence and nicotine in adolescents who smoke on a daily versus a non-daily basis. DESIGN: Repeated measures experiment, non-blinded, involving a single test session. SETTING: Human psychopharmacology laboratory. PARTICIPANTS: Twenty-one daily and 21 non-daily adolescent cigarette smokers (21 females; 21 males; age 13-18 years) with life-time use greater than 10 cigarettes, responding to radio and print advertisements. INTERVENTION: Overnight abstinence from cigarettes followed by smoking of a single cigarette furnished by the participant at test. MEASUREMENTS: The Fagerstrom Test for Nicotine Dependence, saliva nicotine and cotinine, expired air carbon monoxide (CO), heart rate (HR), self-report scales and smoking topography. Most measurements were performed before and after smoking. FINDINGS: Saliva nicotine, CO and HR increased, and self-reported intention and desire to smoke decreased, after smoking (p < 0.001). Fagerstrom scores indicated greater dependence and desire to smoke in daily than in non-daily smokers. HR increased substantially over pre-smoking levels in both groups. Puff topography did not differ between the groups, although collectively these participants appeared to take smaller and more puffs than adult smokers tested under similar conditions. CONCLUSION: This study provides initial evidence that adolescent cigarette smokers self-administer physiologically active doses of nicotine very early in their smoking careers. Nicotine dependence in adolescents appears to be a function of the current frequency of cigarette use, and subjective-behavioral consequences of abstinence and smoking are evident even in non-daily smokers.
Asunto(s)
Nicotina/metabolismo , Fumar/metabolismo , Adolescente , Pruebas Respiratorias/métodos , Monóxido de Carbono/metabolismo , Niño , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Nicotina/efectos adversos , Saliva/metabolismo , Fumar/fisiopatología , Fumar/psicologíaRESUMEN
RATIONALE: Although adolescent smokers appear to display some of the hallmark features of dependence, the biological and behavioral effects of smoking in this population are poorly understood. OBJECTIVES: This study aimed to define empirically the effects of abstinence and smoking in adolescent smokers, using indices validated in adult smokers. METHODS: Subjects were 16 young novice smokers (five male, 11 female), ages 14-18 years. A modified Stroop task measured the ability to inhibit attention to smoking-related cues; the classic Stroop task measured the ability to inhibit a pre-potent response (i.e. reading a word); a rapid information processing (RIP) task measured vigilance. RESULTS: Abstinence increased and smoking decreased the intrusiveness of smoking cues. Parallel effects were seen in commission errors on the RIP task. These effects were restricted to heavier smokers (>11 cigarettes/day). Subjective withdrawal effects predicted the intrusiveness of smoking words during abstinence. The number of cigarettes smoked per day predicted the beneficial effect of smoking on the classic as well as modified Stroop tasks. The physiological effects of abstinence and smoking predicted RIP performance. CONCLUSIONS: Abstinence impairs and smoking improves inhibitory information processing in young novice smokers in a manner similar to adult smokers. Daily frequency of smoking is a critical moderator of these effects.
Asunto(s)
Procesos Mentales/efectos de los fármacos , Cese del Hábito de Fumar/psicología , Fumar/psicología , Adolescente , Atención/efectos de los fármacos , Señales (Psicología) , Femenino , Humanos , Masculino , Pruebas Neuropsicológicas , Desempeño Psicomotor/efectos de los fármacos , Síndrome de Abstinencia a Sustancias/psicología , Encuestas y CuestionariosRESUMEN
The aim of this study was to assess the effects of a single dose of nicotine (NIC, 0.3 or 1.0 mg/kg, s.c.), after survival times of 30, 60 or 120 min, on immediate early gene expression in the pedunculopontine mesencephalic tegmentum (PMT), using Fos-immunocytochemistry. Either doses of NIC strongly increased Fos-immunoreactivity in both the pedunculopontine tegmental nucleus (PPTg) and the laterodorsal tegmental nucleus (LDTg), as compared to the saline controls, at 30 min and 60 min. In comparison, the effects of NIC-induced Fos expression in the caudate-putamen (CP) were not as strong as the ones observed in the PPTg and LDTg. In fact, at 30 min the 0.3 mg/kg dose of NIC did not induce Fos-expression, unlike the PPTg and LDTg. The CP response was more noticeable in the mediodorsal than in the laterodorsal region. Double-labelling studies using Fos-immunoreactivity and NADPH-diaphorase histochemistry for cholinergic cells in the PPTg and LDTg revealed that, in general, cholinergic neurons had Fos negative nuclei, although double-labelled neurons were occasionally seen in the PPTg. In conclusion, systemically administered NIC activates the neuronal population of the PPTg and the LDTg possibly by directly targeting nicotinic receptors that may be located in non-cholinergic neurons. We postulate that activation of these non-cholinergic neurons modulates the activity of cholinergic cells in the PMT, which in turn may alter dopamine release in the mesolimbic system.
Asunto(s)
Regulación de la Expresión Génica/efectos de los fármacos , Genes fos/efectos de los fármacos , Mesencéfalo/metabolismo , Nicotina/toxicidad , Agonistas Nicotínicos/toxicidad , Puente/metabolismo , Tegmento Mesencefálico/metabolismo , Animales , Supervivencia Celular/efectos de los fármacos , Inmunohistoquímica , Masculino , Mesencéfalo/citología , Mesencéfalo/efectos de los fármacos , NADPH Deshidrogenasa/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Sistema Nervioso Parasimpático/efectos de los fármacos , Sistema Nervioso Parasimpático/fisiología , Puente/citología , Puente/efectos de los fármacos , Ratas , Ratas Long-Evans , Tegmento Mesencefálico/citología , Tegmento Mesencefálico/efectos de los fármacosRESUMEN
Neuronal nicotinic receptors are comprised of combinations of alpha(2-9) and beta(2-4) subunits arranged to form a pentameric receptor. Currently, the principal central nervous system (CNS) subtypes are believed to be alpha(4)beta(2) and a homomeric alpha(7) receptor, although other combinations almost certainly exist. The identity of the nicotinic receptor subtype(s) involved in the rewarding effects of nicotine are unknown. In the present study, using some recently described subtype selective nicotinic agonists and antagonists, we investigated the role of the alpha(7) nicotinic receptor in the mediation of nicotine-induced hyperactivity and self-administration in rats. The alpha(7) receptor agonists AR-R 17779 and DMAC failed to stimulate locomotor activity in both nicotine-nontolerant and -sensitized rats. In contrast, nicotine and the putative alpha(4)beta(2) subtype selective agonist SIB1765F increased activity in both experimental conditions. In nicotine-sensitized rats, the high affinity (including the alpha(4)beta(2) subtype) nicotinic antagonist dihydro-beta-erythroidine (DHbetaE), but not the selective alpha(7) antagonist methyllycaconitine (MLA), antagonized a nicotine-induced hyperactivity. Similarly, DHbetaE, but not MLA, pretreatment reduced nicotine self-administration. Electrophysiology experiments using Xenopus oocytes expressing the human alpha(7) receptor confirmed AR-R 17779 and DMAC to be potent agonists at this site, and further studies demonstrated the ability of systemically administered AR-R 17779 to penetrate into the CNS. Taken together, these results indicate a negligible role of alpha(7) receptors in nicotine-induced hyperlocomotion and reward in the rat, and support the view for an involvement of a member from the high-affinity nicotinic receptor subclass, possibly alpha(4)beta(2). Issues such as drug potency, CNS penetration, and desensitization of the alpha(7) receptor are discussed.
Asunto(s)
Actividad Motora/fisiología , Nicotina/farmacología , Receptores Nicotínicos/fisiología , Animales , Hidrocarburos Aromáticos con Puentes/líquido cefalorraquídeo , Hidrocarburos Aromáticos con Puentes/farmacología , Electrofisiología , Humanos , Técnicas In Vitro , Ligandos , Masculino , Agonistas Nicotínicos/farmacología , Oocitos/metabolismo , Piridinas/farmacología , Pirrolidinas/farmacología , Ratas , Ratas Long-Evans , Ratas Sprague-Dawley , Receptores Nicotínicos/efectos de los fármacos , Recompensa , Autoadministración , Compuestos de Espiro/líquido cefalorraquídeo , Compuestos de Espiro/farmacología , Transfección , Xenopus laevis , Receptor Nicotínico de Acetilcolina alfa 7RESUMEN
RATIONALE: The mesolimbic dopamine system has been implicated in the reinforcing effects of nicotine, a drug which appears to act at least in part through the ventral tegmental area (VTA). Other neuronal elements in the VTA are important in drug reward. In particular, mu opioid receptors in the VTA have been shown to influence cocaine reinforcement. OBJECTIVE: The aim of this study was to test whether the mu opioid receptors in the VTA also regulate the intake of nicotine. METHODS: This research was carried out with animals trained to self-administer nicotine or cocaine, or to respond for food. Mu receptors were targeted with the selective agonist [D-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin (DAMGO) and gamma-aminobutyric acid (GABA) receptors with the selective agonists baclofen and muscimol; each of these compounds was delivered by microinfusion into the VTA. RESULTS: The mu-selective agonist DAMGO, tested over a dose range of 0.005-0.05 microg, had an effect at the highest dose only, where it produced a reduction in self-administration maintained by doses of either 10 microg/kg or 30 microg/kg per infusion of nicotine. Intra-VTA microinfusions of DAMGO did not reinstate extinguished responding previously established for nicotine, nor did they have prominent effects on operant behavior maintained by food. In contrast to the overall limited effects of DAMGO on nicotine self-administration, the GABA agonists muscimol and baclofen each reduced nicotine self-administration substantially when delivered into the VTA, whereas they were less effective against cocaine self-administration. CONCLUSIONS: The lesser effect of DAMGO microinfusions in the VTA on nicotine than cocaine self-administration is associated with the opposite efficacy of GABA agonists. These findings suggest that nicotine and cocaine differentially activate circuitry in which mu receptors are situated, especially GABAergic elements.
Asunto(s)
Nicotina/farmacología , Receptores de GABA/metabolismo , Receptores Opioides mu/metabolismo , Área Tegmental Ventral/metabolismo , Analgésicos Opioides/farmacología , Animales , Transporte Biológico , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Masculino , Nicotina/administración & dosificación , Nicotina/farmacocinética , Agonistas Nicotínicos/administración & dosificación , Agonistas Nicotínicos/farmacocinética , Ratas , Ratas Long-Evans , Autoadministración , Área Tegmental Ventral/efectos de los fármacosRESUMEN
BACKGROUND: Alcohol and nicotine, in the form of tobacco, are commonly co-abused. Nicotinic receptors also have been implicated in alcohol action. We designed the present study to examine the possible involvement of nicotinic receptors in alcohol self-administration. METHODS AND RESULTS: Pretreatment with lower doses (0.1-0.4 mg/kg) of nicotine, administered acutely or chronically, did not affect alcohol consumption, whereas a higher dose (0.8 mg/kg) initially suppressed alcohol consumption but stimulated alcohol consumption on repeated treatment. We observed the same pattern of nicotine effects on alcohol self-administration using an operant procedure. A dose of 0.8 mg/kg of nicotine initially suppressed operant responding for alcohol. Such suppression of alcohol self-administration was more pronounced during the first 20 min of the 60 min operant session. Responding for alcohol in the nicotine treated group, however, was significantly increased above the saline treated group by the 5th day of treatment. Mecamylamine, a noncompetitive nicotinic receptor antagonist, reduced alcohol consumption, whereas dihydro-beta-erythroidine (DHbetaE), a competitive nicotinic receptor antagonist, did not modify alcohol consumption. CONCLUSIONS: The stimulation of alcohol intake induced by nicotine treatment and the suppression of alcohol intake induced by mecamylamine provide evidence for the involvement of nicotinic receptors in alcohol consumption and/or self-administration. The failure of DHbetaE to reduce alcohol consumption, however, suggests that ethanol-nicotine interaction is mediated by other nicotinic receptor subtypes rather than alpha4beta2 receptor subtype, or that mecamylamine acts through a nonnicotinic mechanism.
Asunto(s)
Consumo de Bebidas Alcohólicas , Condicionamiento Operante/efectos de los fármacos , Nicotina/farmacología , Agonistas Nicotínicos/farmacología , Receptores Nicotínicos/efectos de los fármacos , Consumo de Bebidas Alcohólicas/psicología , Animales , Dihidro-beta-Eritroidina/farmacología , Masculino , Mecamilamina/farmacología , Antagonistas Nicotínicos/farmacología , Ratas , Ratas Wistar , AutoadministraciónRESUMEN
The objective of this study was to determine whether the pedunculopontine tegmental nucleus plays a role in the maintenance of nicotine self-administration, and whether the ascending cholinergic projection from this nucleus to midbrain dopamine neurons in the ventral tegmental area might be involved. Studies were done with rats trained to self-administer nicotine intravenously. Self-administration was examined before and after the pedunculopontine tegmental nucleus was lesioned with the ethylcholine mustard aziridinium ion, a selective cholinergic toxin. Lesions were assessed qualitatively and quantitatively in histological sections stained for either nicotinamide adenine dinucleotide phosphate-diaphorase histochemistry to identify cholinergic neurons, or for Nissl. Self-administration was also tested after an acute manipulation in which microinfusions of the nicotinic cholinergic antagonist dihydro-beta-erythroidine were made into the pedunculopontine tegmentum. Infusions of neurotoxin into the pedunculopontine tegmentum reduced nicotine self-administration behaviour when tested weeks later. Toxin treatment reduced the number of cholinergic neurons in the tegmentum, while largely sparing the non-cholinergic population in this area. Lesions were limited to the pedunculopontine area and did not extend to the neighboring laterodorsal tegmental nucleus or to the substantia nigra. Acute manipulation of the pedunculopontine tegmental nucleus with microinfusions of dihydro-beta-erythroidine also produced an attenuation of nicotine self-administration. Collectively these data show that the pedunculopontine tegmental nucleus is part of the neuronal circuitry mediating nicotine self-administration, and that the population of cholinergic neurons is likely a critical element.
Asunto(s)
Acetilcolina/metabolismo , Conducta Animal/efectos de los fármacos , Conducta Animal/fisiología , Fibras Colinérgicas/efectos de los fármacos , Fibras Colinérgicas/metabolismo , Degeneración Nerviosa/inducido químicamente , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Nicotina/farmacología , Agonistas Nicotínicos/farmacología , Puente/efectos de los fármacos , Puente/metabolismo , Tegmento Mesencefálico/efectos de los fármacos , Tegmento Mesencefálico/metabolismo , Animales , Aziridinas/farmacología , Colina/análogos & derivados , Colina/farmacología , Fibras Colinérgicas/ultraestructura , Desnervación , Dihidro-beta-Eritroidina/farmacología , Agonistas de Aminoácidos Excitadores/farmacología , Ácido Iboténico/farmacología , Masculino , Bloqueantes Neuromusculares/farmacología , Neuronas/citología , Neurotoxinas/farmacología , Puente/citología , Ratas , Ratas Long-Evans , Autoadministración , Tegmento Mesencefálico/citología , Tabaquismo/fisiopatologíaRESUMEN
RATIONALE: The pedunculopontine tegmental nucleus (PPTg) has been implicated in drug reward, particularly in the development of dependence. However, little is known of the receptor systems within this nucleus which might be involved. Furthermore, some research suggests that the PPTg may also be part of the neuronal circuitry involved in established drug-taking behavior. OBJECTIVE: The objective of these experiments was to examine the role of mu-opioid and nicotinic cholinergic mechanisms in the PPTg in cocaine self-administration. METHODS: Microinfusions of mu-opioid and nicotinic receptor selective compounds were made into the PPTg of rats trained to self-administer cocaine intravenously, in the vicinity of cholinergic cells which are known to project to the midbrain dopamine neurons of the ventral tegmental area (VTA). RESULTS: The mu-opioid selective agonist DAMGO, tested at doses of 0, 0.05 and 0.5 microg, produced a dose-related reduction in the number of cocaine infusions obtained during the 1-h self-administration sessions. The mu-selective antagonist CTOP (0-2 microg) and nicotine (0-10 microg) did not produce significant changes in cocaine self-administration. Microinfusions of the nicotinic antagonist dihydro-beta-erythroidine (0-30 microg) produced a small but significant increase in cocaine-maintained responding. CONCLUSIONS: These data show that mu-opioid mechanisms in the PPTg can influence cocaine self-administration markedly. Moreover, the data demonstrate that PPTg circuitry can influence drug reward in already-established drug-reinforced behavior, as well as during the development of dependence (as shown by previous research).
Asunto(s)
Cocaína/administración & dosificación , Puente/fisiología , Receptores Nicotínicos/fisiología , Receptores Opioides mu/fisiología , Animales , Encefalina Ala(2)-MeFe(4)-Gli(5) , Encefalinas/farmacología , Masculino , Microinyecciones , Ratas , Ratas Long-Evans , Autoadministración , Somatostatina/análogos & derivados , Somatostatina/farmacología , Área Tegmental Ventral/efectos de los fármacos , Área Tegmental Ventral/fisiologíaRESUMEN
Microinfusions of the opioid subtype-selective agonist DAMGO and antagonist CTOP into the ventral tegmental area (VTA) were used to examine the role of mu opioid receptors in this area of the mesolimbic dopamine system in regulating cocaine reinforcement. Long-Evans rats were trained to self-administer cocaine intravenously and prepared with intracranial cannulae directed to the VTA. At doses of cocaine on the descending limb of the cocaine dose-response curve, the mu-selective agonist DAMGO produced a dose-related decrease in cocaine self-administration when delivered by microinfusion into the VTA. At a dose of cocaine on the ascending limb of the self-administration dose-response curve, DAMGO microinfusions produced an increase in responding for the drug. The mu-selective antagonist CTOP produced small effects on cocaine self-administration. A kappa-selective agonist and antagonist (U50,488 and norbinaltorphimine, respectively) produced either no effects or small effects that did not show consistent trends with dose. These experiments suggest that the mu agonist DAMGO is able to shift the dose-response curve for cocaine self-administration to the left. This effect appears to be specific for mu as compared to kappa agonists. These data are consistent with the known differential distribution of opioid receptor subtypes within the VTA, and with the effects of opioid compounds in the VTA on dopamine release in the mesolimbic synaptic field. The data show that a mu opioid mechanism in the somatodendritic region can alter reinforcement processes for cocaine, which acts predominantly at the terminal field of dopamine cells.
Asunto(s)
Analgésicos Opioides/farmacología , Cocaína/farmacología , Encefalinas/farmacología , Receptores Opioides mu/agonistas , Área Tegmental Ventral/metabolismo , Animales , Inhibidores de Captación de Dopamina/farmacología , Encefalina Ala(2)-MeFe(4)-Gli(5) , Inyecciones Intravenosas , Masculino , Ratas , Ratas Long-Evans , Receptores Opioides delta/agonistas , Receptores Opioides delta/antagonistas & inhibidores , Autoadministración , Área Tegmental Ventral/efectos de los fármacosRESUMEN
Various animal models of nicotine dependence now exist. To study the positive reinforcing effects of nicotine, there are choices of animal species, strains, and operant paradigms to use. This manuscript describes the use of one particular paradigm, a model in which work is done by laboratory animals to obtain intravenous infusions of nicotine. This model is particularly useful for examining the mechanisms in the brain that are responsible for the maintenance of drug-taking behavior. Two examples of ongoing studies of the mechanisms of dependence are discussed: the role of cholinergic projections to midbrain dopamine cells, and the influence of opioid receptors in the vicinity of these same dopamine cells.
Asunto(s)
Conducta Adictiva/fisiopatología , Modelos Animales de Enfermedad , Nicotina/farmacología , Tabaquismo/fisiopatología , Animales , Sistema Límbico/efectos de los fármacos , Sistema Límbico/metabolismo , Receptores Opioides/efectos de los fármacos , Receptores Opioides/metabolismo , Reproducibilidad de los Resultados , Autoadministración , Área Tegmental Ventral/efectos de los fármacos , Área Tegmental Ventral/metabolismoRESUMEN
Acamprosate (calcium-acetyl homotaurinate) is a new compound used in the treatment of alcohol abuse. Because of the putative link between alcoholism and the endogenous opioid systems in both humans and laboratory animals, we tested in rats the effects of acamprosate on behavioral and neurochemical effects of opioid drugs related to their abuse potential. These included sensitization to the behavioral effects of morphine, morphine-induced dopamine (DA) release in the nucleus accumbens (NAS), intravenous (i.v.) heroin self-administration and relapse to heroin seeking in drug-free rats. In experiment 1, rats were injected daily with either morphine (10 mg/kg, s.c.) or saline for 14 days. Three days later in a test for the expression of sensitization, an injection of morphine (10 mg/kg) resulted in increased locomotor activity and enhanced DA release in the NAS in rats previously exposed to morphine. Acamprosate (two injections of 200 mg/kg, 12 h apart; i.p.) suppressed the expression of the sensitized responses, but did not alter the effects of morphine in drug-naive control rats. In experiment 2, it was found that acamprosate (two injections of 50-200 mg/ kg; i.p.) had no consistent effects on i.v. heroin self-administration (50 100 microg/kg per infusion) and, in experiment 3, that acamprosate (100-200 mg/ kg, i.p.) did not alter reinstatement of drug seeking induced by priming injections of heroin (0.25 mg/kg, s.c.) or a footshock stressor (15 min; 0.5 mA) after a 5- to 8-day period of extinction. Thus, although acamprosate attenuated the expression of sensitized locomotor activity and DA release in the NAS, it did not have any consistent effect on either the intake of heroin during the maintenance phase or the relapse to heroin seeking in a drug-free state. Thus, to the extent that the self-administration and the reinstatement procedures provide valid preclinical models for drug use and relapse in humans, our data suggest that acamprosate may not be effective in altering drug-taking behavior in heroin users.
Asunto(s)
Dependencia de Heroína/tratamiento farmacológico , Heroína/farmacología , Morfina/farmacología , Taurina/análogos & derivados , Acamprosato , Animales , Interacciones Farmacológicas , Tolerancia a Medicamentos , Privación de Alimentos , Masculino , Narcóticos/farmacología , Ratas , Ratas Sprague-Dawley , Recurrencia , Autoadministración , Estrés Fisiológico/fisiopatología , Taurina/farmacologíaRESUMEN
In rats, amphetamine (AMP) conversion to 4-OH-AMP is metabolized by CYP2D1, the rat equivalent of the human enzyme CYP2D6. To determine the impact of impaired AMP metabolism on its behavioural effects, AMP-induced hyperactivity, AMP discrimination and AMP self-administration were examined in male Wistar rats with or without pretreatment with the CYP2D1 inhibitors quinine and budipine. In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) increased the plasma area under the curve of AMP 4-fold and 3.6-fold respectively, and decreased the plasma levels of 4-OH-AMP, 3-fold and 8.6-fold, confirming that the doses used suppressed CYP2D1 activity. Both inhibitors prolonged AMP-induced hyperactivity (0.3 mg/kg) and prolonged the duration of AMP-appropriate responding for periods of up to 90 min post-AMP administration in a drug discrimination procedure. In rats given a preload dose of AMP (0.8 mg/kg) 3 h prior to the self-administration test session, CYP2D1 inhibition resulted in fewer AMP infusions being taken compared with rats receiving the AMP preload dose alone. These studies indicate that AMP is responsible for the behavioural effects seen in rats and that a rat phenocopy model of the human CYP2D6 deficiency state can be produced by CYP2D1 inhibitors.
Asunto(s)
Hidrocarburo de Aril Hidroxilasas , Conducta Animal/efectos de los fármacos , Estimulantes del Sistema Nervioso Central/farmacología , Inhibidores Enzimáticos del Citocromo P-450 , Dextroanfetamina/farmacología , Inhibidores Enzimáticos/farmacología , Oxidorreductasas de Alcohol , Animales , Familia 2 del Citocromo P450 , Dextroanfetamina/farmacocinética , Discriminación en Psicología/efectos de los fármacos , Interacciones Farmacológicas , Generalización del Estimulo/efectos de los fármacos , Masculino , Actividad Motora/efectos de los fármacos , Piperidinas/farmacología , Quinina/farmacología , Ratas , Ratas Wistar , Autoadministración/psicología , p-Hidroxianfetamina/sangreRESUMEN
Reinstatement and spontaneous recovery of previously extinguished nicotine-taking behavior were examined in rats. Male subjects were trained to self-administer nicotine (30 microg/kg per infusion, IV; one 60-min session per day for 3 weeks). Extinction sessions were then given for 5-10 days during which saline was substituted for nicotine. Subsequently, in the first set of tests for nicotine seeking, the reinstatement of lever presses that previously delivered nicotine was examined after priming injections of saline and nicotine (75, 150 and 300 microg/kg, SC; and 30 and 60 microg/kg, IV). In the second set of tests for nicotine-seeking, rats were tested after an additional 21-day drug-free period during which they were not exposed to the self-administration chambers (a test for the spontaneous recovery of drug seeking), and after priming injections of nicotine (150 and 300 microg/kg, SC). Reinstatement of extinguished food-reinforced behavior after exposure to nicotine was also determined. Priming injections of nicotine reinstated nicotine seeking regardless of the route of administration. In addition, previously extinguished nicotine seeking recovered spontaneously after a 21-day period during which rats were not exposed to the drug-taking environment. Nicotine also reinstated extinguished food-reinforced behavior in rats with a history of nicotine self-administration, but not in drug-naive rats. The present results extend previous work with opioid and stimulant drugs on reinstatement of drug seeking by the self-administered drug. It also appears that, as with other positive reinforcers, the mere passage of time is a sufficient condition for the spontaneous recovery of extinguished nicotine seeking.
Asunto(s)
Condicionamiento Operante/efectos de los fármacos , Extinción Psicológica , Nicotina/farmacología , Agonistas Nicotínicos/farmacología , Animales , Masculino , Ratas , AutoadministraciónRESUMEN
Studies of nicotine self-administration in animal and human subjects are discussed with respect to the behavioral paradigms employed, the effects of nicotine dose manipulations and nicotinic agonist/antagonist pretreatment, and the role of neurochemical processes mediating reinforcement. Animal models have focused on intravenous nicotine self-administration, while most studies in human subjects have studied cigarette smoking behavior. Despite procedural differences, data from both animal and human studies show an inverted-U function relating nicotine dose to self-administration behavior, with maximal rates of responding occurring at intermediate doses of nicotine. Moreover, nicotine supplementation via non-contingent nicotine administration suppresses nicotine self-administration behavior in both animal models and human cigarette smokers. Nicotine antagonist treatment also reduces responding, although human studies usually find a transient increase in smoking, which is interpreted as an attempt to compensate for nicotinic receptor blockade. Amongst the neurochemical systems which have been examined, most emphasis has been given to dopamine. The mesolimbic dopamine pathway has been implicated in nicotine reward based on animal studies, and research with humans suggests a role for dopaminergic processes as well. However, dopaminergic blockade appears to increase cigarette smoking behavior in humans, while in animals nicotine self-administration is attenuated. Future research should exploit the complementary aspects of animal models and human paradigms to provide a coherent understanding of nicotine reinforcement. Animal models allow for analysis of anatomical and physiological mechanisms underlying nicotine self-administration; human studies validate the relevance to tobacco dependence and smoking cessation treatment.
Asunto(s)
Nicotina/farmacología , Autoadministración , Animales , Relación Dosis-Respuesta a Droga , HumanosRESUMEN
The influence of cocaine on rat brain monoaminergic neurotransmitters (dopamine, serotonin, noradrenaline) and their metabolites, and on binding of [3H]WIN 35,428 and [3H]GBR 12,935 to the dopamine transporter was measured after 4 weeks of cocaine exposure. Cocaine (mean daily dose 9.25 +/- 0.48 mg/kg) was self-administered (responders) or passively received (yoked) during sessions which lasted for 1 h per day. As compared with the controls, mean dopamine and serotonin levels were significantly elevated (+ 107% and + 47%, respectively) in amygdala of responders, but not of yoked rats, sacrificed 1 h after the last cocaine session. Dopamine and metabolite levels were normal in all other brain areas examined, including striatum, nucleus accumbens and medial prefrontal cortex, at both 1 h and 4 weeks withdrawal from cocaine. [3H]WIN 35,428 and [3H]GBR 12,935 binding were unaltered after cocaine exposure. These data provide additional support for the involvement of the amygdala in the acquisition of drug seeking behavior associated with cocaine self-administration.